PurPose. To evaluate intravitreal bevacizumab (IVB) combined with grid laser photocoagulation in macular edema (ME) secondary to branch retinal vein occlusion (BRVO 1,3,6, and 12 months were 0.47±0.18 (p=0.031), 0.56±0.50 (p=0.031), 0.65±0.60 (p=0.008), and 0.66±0.65 (p=0.016), respectively. The mean CST values at 1,3,6, and 12 months were 295±60 μm (p=0.008), 333±114 μm (p=0.070), 339±80 μm (p=0.008), and 335±109 μm (p=0.008